Thyroid disease in pregnancy requires careful monitoring. The TSH (thyroid-stimulating hormone) target in pregnancy is <2.5 mIU/L in the first trimester — stricter than the non-pregnant reference range. Uncontrolled hypothyroidism can cause miscarriage, pre-eclampsia, and developmental problems in the baby. At Mother Hospitals, Boduppal, thyroid monitoring is built into our antenatal and IVF protocols. Call 97059 93366.
Thyroid disorders are among the most common medical conditions in pregnancy. Early diagnosis, correct TSH targets, and proper dose adjustment of thyroid medication are critical for a safe pregnancy, a healthy baby, and successful IVF. Expert management at Mother Hospitals, Boduppal.
MBBS, DGO, PG Diploma in ART – Kiel University, Germany | 20+ Years Experience | TGMC Reg: 50624
The thyroid gland — a butterfly-shaped gland in the neck — produces hormones (T3 and T4) that regulate metabolism, energy, body temperature, and critically, fetal brain development. In India, thyroid disorders affect approximately 10–15% of pregnant women, with hypothyroidism (underactive thyroid) being the most common. Many cases are subclinical — no obvious symptoms, but abnormal TSH levels that pose significant pregnancy risks if left untreated.
Pregnancy places increased demands on the thyroid gland. In the first trimester, hCG (the pregnancy hormone) stimulates the thyroid, causing a natural slight drop in TSH. Oestrogen increases thyroid-binding globulin (TBG), reducing free thyroid hormone levels. Total thyroid hormone production must increase by 40–50% during pregnancy. Women with pre-existing hypothyroidism or limited thyroid reserve may not be able to meet this increased demand without dose adjustment.
The normal TSH range in non-pregnant adults is typically 0.4–4.0 mIU/L. In pregnancy, these targets are significantly tighter — particularly in the critical first trimester when the baby depends entirely on maternal thyroid hormone for brain development (the fetal thyroid does not begin functioning until 10–12 weeks). Even a TSH of 3.0 mIU/L — normal outside pregnancy — may represent inadequate thyroid function for a developing baby in the first trimester. The American Thyroid Association (ATA) 2017 guidelines and FOGSI recommendations guide our protocol at Mother Hospitals.
Hypothyroidism (underactive thyroid) is the most common thyroid disorder in pregnancy in India. It may be pre-existing and known, or newly diagnosed at the booking visit. Both overt hypothyroidism (raised TSH + low fT4) and subclinical hypothyroidism (raised TSH with normal fT4) require management in pregnancy.
Note: many of these symptoms overlap with normal pregnancy — which is why TSH testing is essential, not just symptom-based assessment.
The treatment for hypothyroidism in pregnancy is levothyroxine (L-thyroxine) — a synthetic T4 hormone. Women already on levothyroxine typically need a 25–50% dose increase from the moment of a positive pregnancy test, because pregnancy demands significantly more thyroid hormone. The exact increase is guided by TSH levels. Women newly diagnosed in pregnancy are started on levothyroxine immediately, with the dose titrated to achieve the trimester-specific TSH target. Levothyroxine is completely safe in pregnancy — it is identical to the hormone the thyroid produces naturally. It should be taken on an empty stomach, 30 minutes before food, and separated from calcium, iron, and prenatal vitamin supplements by at least 4 hours.
These targets are based on ATA 2017 guidelines and FOGSI recommendations. Your individual target may vary slightly based on your anti-TPO antibody status and clinical history — always follow the guidance given by Dr. E. Prashanthi Reddy at your specific consultation.
✦ These are guideline-based targets. Individual targets may be adjusted based on clinical context, anti-TPO antibody status, and history of pregnancy complications. Always discuss your specific target with Dr. E. Prashanthi Reddy.
Subclinical hypothyroidism (SCH) means TSH is elevated but fT4 is still within the normal range — the thyroid is underperforming but compensating. Outside pregnancy, mild SCH (TSH 2.5–4.0) may be monitored without treatment. In pregnancy, the calculation changes significantly.
Anti-thyroid peroxidase (anti-TPO) antibodies are markers of thyroid autoimmunity — the immune system attacking the thyroid gland. Anti-TPO antibodies are present in approximately 10–15% of women of reproductive age in India. Their significance in pregnancy goes beyond thyroid function:
Anti-TPO positive women with completely normal TSH levels still have a 2–3× higher risk of miscarriage compared to antibody-negative women. The mechanism involves immune activation at the implantation site. This is one reason we test anti-TPO antibodies in women with recurrent pregnancy loss, even when TSH appears normal.
Positive anti-TPO antibodies with hypothyroidism indicates Hashimoto's thyroiditis — the most common cause of hypothyroidism in women in India. Hashimoto's is an autoimmune condition that progressively destroys thyroid tissue. Management in pregnancy involves levothyroxine replacement and close TSH monitoring.
Several studies (including the Negro et al. RCT) suggest that treating anti-TPO positive women with euthyroid TSH (normal TSH) with low-dose levothyroxine reduces miscarriage and preterm birth rates. At Mother Hospitals, this is discussed with each patient and a personalised decision is made.
Women with recurrent miscarriage should have anti-TPO antibodies tested. Learn more on our Recurrent Miscarriage page.
Hyperthyroidism (overactive thyroid) is less common than hypothyroidism in pregnancy but requires careful management. The two main causes in pregnancy are gestational hyperthyroidism and Graves' disease.
Caused by hCG stimulating the thyroid in early pregnancy — TSH drops and fT4 rises transiently in the first trimester. Usually accompanies hyperemesis gravidarum (severe morning sickness). Typically resolves by 14–16 weeks without treatment. Anti-thyroid drugs are NOT used for gestational hyperthyroidism — it is self-limiting.
Autoimmune condition where antibodies (TRAb / TSI) continuously stimulate the thyroid. Does not resolve spontaneously. If untreated, carries risks of preterm birth, fetal growth restriction, fetal thyrotoxicosis (from TRAb crossing the placenta), heart failure (thyroid storm), and maternal morbidity. Requires anti-thyroid medication.
Anti-thyroid drug choice changes during pregnancy based on teratogenic risk:
PTU is preferred in the first trimester because carbimazole (CMZ) is associated with a rare embryopathy (aplasia cutis, choanal atresia) if used in weeks 6–10. PTU risk of liver toxicity is lower in the short first-trimester exposure period.
After 14–16 weeks, carbimazole is preferred because PTU carries a higher risk of maternal liver damage with long-term use. The lowest effective dose is used to keep maternal fT4 in the upper-normal range — avoiding fetal hypothyroidism from over-treatment.
Thyroid function is a key parameter in our IVF assessment protocol at Mother Hospitals. This is distinct from the general fertility-thyroid relationship covered on our Thyroid and Fertility page — here we focus specifically on thyroid management during IVF treatment and in early IVF pregnancy.
At Mother Hospitals, we require TSH below 2.5 mIU/L before proceeding to embryo transfer in a fresh or frozen cycle. Ovarian stimulation with high oestrogen levels further suppresses thyroid function — making pre-existing borderline hypothyroidism clinically significant during IVF. We adjust levothyroxine dose if needed before transfer.
We test anti-TPO antibodies in all IVF patients, not just those with known thyroid disease. Positive antibodies — even with a normal TSH — are associated with lower IVF success rates and higher miscarriage rates post-transfer. Low-dose levothyroxine is offered and the evidence discussed.
After a positive beta-hCG following IVF, we recheck TSH within 2–4 weeks. The rapid hormonal changes of early IVF pregnancy (including supraphysiological progesterone and oestrogen from stimulation) can shift TSH significantly. Early rechecking prevents undetected hypothyroidism in the most critical embryonic period.
See also: IVF Treatment Hyderabad | Thyroid and Fertility
This schedule is based on our standard protocol at Mother Hospitals. Women on levothyroxine or with known thyroid disease require more frequent monitoring than those with normal thyroid function on booking.
We follow ATA 2017 and FOGSI guidelines precisely. TSH is tested at every key stage of pregnancy and IVF. We do not wait for symptoms — we test proactively because subclinical thyroid disease is by definition asymptomatic.
Because we offer both IVF and obstetric care under one roof, thyroid management begins before conception — optimising TSH pre-transfer — and continues seamlessly through pregnancy. There is no gap between your fertility care and your antenatal care.
Dr. E. Prashanthi Reddy's PG Diploma in ART from Kiel University, Germany included endocrine management in reproductive medicine — including thyroid protocols for IVF and pregnancy. This international clinical training informs our evidence-based approach.
For women with unexplained recurrent miscarriage, we always include anti-TPO antibody testing and TSH optimisation as part of our investigation protocol — because thyroid autoimmunity is a treatable, often missed cause.
Almost certainly, yes — if you are on levothyroxine. The moment you get a positive pregnancy test, call us on 97059 93366 to arrange an urgent TSH check. Most women need a 25–50% dose increase in the first trimester because pregnancy demands significantly more thyroid hormone. Do not wait for your next scheduled appointment — early optimisation matters enormously for the baby's brain development.
The target in the first trimester is TSH below 2.5 mIU/L — stricter than the normal non-pregnant range (0.4–4.0). This is because the fetal brain depends entirely on maternal thyroid hormone in weeks 4–12. A TSH of 3.5 mIU/L — perfectly normal outside pregnancy — may be inadequate during this critical window. After the first trimester, the target is below 3.0 (second trimester) and below 3.5 (third trimester).
Yes — this is one of the most important reasons to optimise thyroid function before and during pregnancy. Overt hypothyroidism significantly increases miscarriage risk, particularly in the first trimester when the baby has no independent thyroid function. Even subclinical hypothyroidism with TSH above 4.0, and anti-TPO antibody positivity even with normal TSH, are associated with increased miscarriage rates. Correct treatment with levothyroxine substantially reduces this risk.
Yes — levothyroxine is entirely safe in pregnancy and is the recommended treatment for hypothyroidism in pregnant women. It is identical to the thyroid hormone your own gland produces. It does not cross the placenta in significant amounts. It does not cause birth defects. In fact, untreated hypothyroidism poses far greater risks to the pregnancy than levothyroxine treatment. There is no reason to stop or reduce levothyroxine in pregnancy — the opposite is usually needed.
With properly managed thyroid disease in pregnancy, most women deliver healthy babies with normal development. The risks from thyroid disease arise when it is uncontrolled or undiagnosed. The fetal brain is most vulnerable in the first trimester, which is why early diagnosis, rapid treatment, and regular monitoring matter so much. Once TSH is within the target range and maintained there throughout pregnancy, the risk to the baby is very substantially reduced.
Yes — thyroid function should be rechecked in every pregnancy, even if it was normal in a previous one. Thyroid function can change between pregnancies, particularly with age, weight changes, or the passage of time in women with Hashimoto's. If you had hypothyroidism in a previous pregnancy, it must be assumed present in the current one and treatment initiated (or dose increased) immediately. Do not wait for a TSH result before acting if you are on levothyroxine.
Yes, with appropriate medication management. Propylthiouracil (PTU) is considered safe in breastfeeding — very little passes into breast milk. Carbimazole / methimazole passes into breast milk in slightly higher amounts but is generally considered acceptable at low to moderate doses. Your doctor will choose the lowest effective dose and advise specific timing (taking the dose after a feed and waiting before the next). Untreated maternal hyperthyroidism is more concerning for the baby than the medication.
Yes — thyroid status at the time of IVF matters. TSH above 2.5 at embryo transfer is associated with lower implantation rates and higher early pregnancy loss. Anti-TPO antibody positivity, even with a normal TSH, is associated with lower IVF success rates in multiple studies. At Mother Hospitals, we screen and optimise thyroid function before all IVF cycles and require TSH below 2.5 before embryo transfer. This is one of several evidence-based steps we take to maximise your IVF success rate.
Dr. E. Prashanthi Reddy · TGMC Reg: 50624